Lipid Metabolism Practice Questions

Q: Hypertriglyceridemia is not a feature of which of the following conditions?

Alcoholism. **Explanation:** This question appears to have a technical error in its framing or key, as **Alcoholism, Obesity, Diabetes Mellitus, and Pregnancy are all classic causes of Hypertriglyceridemia.** However, in the context of standard medical examinations, if one must be excluded based on the *primary* lipid profile change or the *mechanism* of lipid elevation, the reasoning is as follows: 1. **Alcoholism (Correct Answer per key):** While chronic alcohol consumption typically **increases** VLDL and triglycerides (by increasing the NADH/NAD+ ratio, which promotes fatty acid synthesis), some examiners argue that its hallmark is fatty liver (steatosis) rather than isolated systemic hypertriglyceridemia, or they may be contrasting it with the more "direct" metabolic syndromes. *Note: Clinically, alcohol is a major cause of Type IV hyperlipidemia.* 2. **Obesity:** Strongly associated with hypertriglyceridemia. Increased adipose tissue leads to higher flux of free fatty acids to the liver, stimulating VLDL production. 3. **Diabetes Mellitus:** Insulin deficiency or resistance decreases the activity of **Lipoprotein Lipase (LPL)**. Since LPL is required to clear chylomicrons and VLDL, its deficiency leads to significant hypertriglyceridemia. 4. **Pregnancy:** A physiological state of hyperlipidemia. Estrogen increases VLDL synthesis, and insulin resistance in the third trimester decreases LPL activity to ensure nutrient availability for the fetus. **High-Yield Clinical Pearls for NEET-PG:** * **LPL Activator:** Insulin and Apo C-II. * **LPL Inhibitor:** Apo C-III and Angiopoietin-like protein 4. * **Eruptive Xanthomas:** Characteristic skin finding when serum triglycerides exceed 1000 mg/dL. * **Acute Pancreatitis:** A critical complication of severe hypertriglyceridemia. * **Alcohol's effect:** Increases NADH, leading to increased alpha-glycerophosphate, which provides the backbone for triglyceride synthesis.

Q: Which one of the following is of highest predictive value in the morbidity of coronary heart disease?

Apolipoprotein B. **Explanation:** **Apolipoprotein B (ApoB)** is considered the most accurate predictor of coronary heart disease (CHD) risk because it provides a direct measure of the total number of atherogenic particles. Each particle of VLDL, IDL, and LDL contains exactly **one molecule of ApoB-100**. While LDL-C measures the cholesterol *volume* within particles (which can vary), ApoB reflects the actual *particle count*. Since smaller, denser LDL particles are more prone to oxidation and arterial wall penetration, a high ApoB count indicates a higher "atherogenic burden," even if total LDL-C levels appear normal. **Analysis of Incorrect Options:** * **Low-Density Lipoprotein (LDL):** While traditionally used as the primary target for therapy, LDL-C can be misleading in patients with metabolic syndrome or diabetes who have small, dense LDL particles. ApoB has been shown in recent trials (like the INTERHEART study) to be a superior predictor compared to LDL-C. * **Lipoprotein (a) [Lp(a)]:** This is an independent genetic risk factor for CHD. While highly significant, it is not as strong a universal predictor of morbidity as the total ApoB count. * **Apolipoprotein A (ApoA-1):** This is the primary protein associated with HDL (the "good" cholesterol). A *low* level of ApoA-1 is associated with risk, but it is the **ApoB/ApoA-1 ratio** (rather than ApoA alone) that is a strong predictor. **High-Yield Clinical Pearls for NEET-PG:** * **ApoB-100** is found in VLDL, IDL, and LDL (liver-derived). * **ApoB-48** is found in Chylomicrons (intestine-derived). * **Friedewald Formula:** LDL = Total Cholesterol – [HDL + (Triglycerides/5)]. This formula is invalid if TG >400 mg/dL. * **ApoB/ApoA-1 ratio** is often cited as the single most important lipid parameter for predicting myocardial infarction risk.

Q: All of the following statements about fatty acid synthesis are true, except:

Palmitoleic acid is the end product. **Explanation:** The correct answer is **D**, as the primary end product of the fatty acid synthase (FAS) complex is **Palmitic acid (Palmitate)**, a 16-carbon saturated fatty acid. Palmitoleic acid is a monounsaturated fatty acid (16:1) formed later by desaturation in the endoplasmic reticulum. **Analysis of Options:** * **A. Occurs in cytosol:** This is true. Unlike fatty acid oxidation (which occurs in the mitochondria), synthesis takes place in the cytoplasm, primarily in the liver, lactating mammary glands, and adipose tissue. * **B. Citrate shuttle is required:** This is true. Acetyl CoA is produced in the mitochondria but cannot cross the inner mitochondrial membrane. It condenses with oxaloacetate to form **Citrate**, which is shuttled into the cytosol and cleaved back into Acetyl CoA and oxaloacetate by *ATP-citrate lyase*. * **C. Acetyl CoA is the immediate substrate:** This is true. Acetyl CoA serves as the initial primer and the building block (after conversion to Malonyl CoA) for the synthesis of the carbon chain. **High-Yield NEET-PG Pearls:** * **Rate-limiting enzyme:** Acetyl CoA Carboxylase (ACC), which requires **Biotin** (Vitamin B7) as a cofactor. * **Reductant:** **NADPH** is the essential electron donor, primarily supplied by the Hexose Monophosphate (HMP) Shunt. * **Multienzyme Complex:** In humans, Fatty Acid Synthase is a dimer with seven different catalytic activities on a single polypeptide chain, including the **Acyl Carrier Protein (ACP)** which contains Vitamin B5 (Pantothenic acid). * **Inhibitor:** Malonyl CoA inhibits *Carnitine Palmitoyltransferase-I (CPT-I)*, preventing simultaneous synthesis and degradation of fatty acids (preventing a futile cycle).

Q: Malonyl coenzyme A decarboxylase has an activity of how many enzymes?

2. **Explanation:** The correct answer is **2** because **Malonyl-CoA Decarboxylase (MCD)** is a bifunctional enzyme. In humans, it is encoded by the *MLYCD* gene and exhibits two distinct enzymatic activities: 1. **Decarboxylase activity:** It catalyzes the conversion of malonyl-CoA into acetyl-CoA and carbon dioxide. This is its primary role in regulating fatty acid oxidation. 2. **Malonyltransferase activity:** It is involved in the malonylation of proteins (a post-translational modification), specifically acting as a malonyltransferase to regulate metabolic pathways. **Analysis of Options:** * **Option A (1):** Incorrect. While many enzymes are monofunctional, MCD is specifically recognized in biochemistry for its dual regulatory roles. * **Option C & D (3 & 4):** Incorrect. These options overestimate the functional domains of the MCD protein. Complex multi-enzyme systems like Fatty Acid Synthase (FAS) have 7 activities, but MCD is strictly bifunctional. **Clinical Pearls & High-Yield Facts:** * **Regulation of Beta-Oxidation:** Malonyl-CoA is a potent inhibitor of **Carnitine Palmitoyltransferase I (CPT-1)**. By decarboxylating malonyl-CoA, MCD relieves this inhibition, allowing fatty acids to enter the mitochondria for oxidation. * **Malonic Aciduria:** A deficiency in MCD leads to Malonic Aciduria, characterized by developmental delay, seizures, and cardiomyopathy due to the toxic buildup of malonic acid and impaired energy metabolism. * **Metabolic Target:** MCD inhibitors are being researched as potential treatments for obesity and type 2 diabetes, as they increase malonyl-CoA levels, thereby shifting metabolism from fat oxidation to glucose oxidation.

Q: Bile acids are derived from what substance?

Cholesterol. **Explanation:** **Why Cholesterol is Correct:** Bile acids are the primary end-products of cholesterol catabolism. This conversion occurs exclusively in the liver. The process begins with the hydroxylation of cholesterol, catalyzed by the rate-limiting enzyme **7-alpha-hydroxylase** (which requires Vitamin C and NADPH). The primary bile acids formed are **Cholic acid** and **Chenodeoxycholic acid**. These are then conjugated with glycine or taurine to form bile salts, which are essential for the emulsification and absorption of dietary lipids and fat-soluble vitamins. **Why Other Options are Incorrect:** * **Fatty acids:** While fatty acids are components of many lipids (like triglycerides), they are oxidized via beta-oxidation to produce energy (Acetyl-CoA) and are not precursors to the steroid nucleus of bile acids. * **Bilirubin:** Bilirubin is the breakdown product of **Heme** (from hemoglobin). While both bile acids and bilirubin are components of bile, they have entirely different metabolic origins. * **Proteins:** Proteins are broken down into amino acids. While some amino acids (glycine/taurine) are used to *conjugate* bile acids, the core structure of the bile acid is derived from lipid metabolism, not protein. **High-Yield NEET-PG Pearls:** * **Rate-limiting enzyme:** 7-alpha-hydroxylase (inhibited by bile acids via feedback inhibition). * **Primary vs. Secondary:** Primary bile acids (Cholic/Chenodeoxycholic) are made in the liver. Secondary bile acids (**Deoxycholic/Lithocholic**) are formed by bacterial action in the intestine. * **Enterohepatic Circulation:** Approximately 95% of bile salts are reabsorbed in the **terminal ileum** and returned to the liver. * **Clinical Link:** Bile acid sequestrants (like Cholestyramine) lower blood cholesterol by preventing reabsorption, forcing the liver to use more cholesterol to synthesize new bile acids.

Q: What is the principal precursor of cholesterol?

Acetate. **Explanation:** The synthesis of cholesterol (sterolgenesis) is a complex process occurring primarily in the liver and intestines. **1. Why Acetate is Correct:** The fundamental building block for all 27 carbon atoms of cholesterol is **Acetate**, which enters the biosynthetic pathway in the form of **Acetyl-CoA**. Two molecules of Acetyl-CoA condense to form Acetoacetyl-CoA, which then reacts with a third Acetyl-CoA to form HMG-CoA. This pathway eventually leads to the formation of mevalonate, the committed step in cholesterol synthesis. **2. Why the other options are incorrect:** * **Citrate:** While citrate acts as a carrier to transport Acetyl-CoA from the mitochondria to the cytosol (where cholesterol synthesis occurs), it is a transport intermediate, not the direct precursor. * **Glycerol:** This is a precursor for the synthesis of Triacylglycerols (TAGs) and phospholipids, but it does not contribute to the steroid nucleus. * **Lanosterol:** This is the **first steroid intermediate** formed during the cyclization of squalene. While it is a part of the pathway, it is a late-stage intermediate rather than the "principal precursor." **Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** HMG-CoA Reductase (converts HMG-CoA to Mevalonate). * **Pharmacology Link:** **Statins** (e.g., Atorvastatin) are competitive inhibitors of HMG-CoA Reductase. * **Subcellular location:** Synthesis occurs in the **Cytosol** and **Endoplasmic Reticulum**. * **Key Intermediate:** **Squalene** is the 30-carbon precursor that undergoes cyclization to form Lanosterol.

Q: Which of the following uses ketone bodies, except?

Hepatocytes. **Explanation:** The correct answer is **Hepatocytes (Option D)**. The utilization of ketone bodies (ketolysis) requires the enzyme **Thiophorase** (also known as Succinyl-CoA:3-ketoacid CoA transferase). While the liver is the primary site of **ketogenesis** (production of ketone bodies), it lacks the enzyme Thiophorase. Therefore, the liver can produce ketone bodies but cannot utilize them for energy, ensuring that ketone bodies are exported to peripheral tissues during starvation. **Analysis of other options:** * **Brain (Option A):** During prolonged starvation, the brain adapts to use ketone bodies (specifically 3-hydroxybutyrate and acetoacetate) as its primary energy source, meeting up to 75% of its energy requirements to spare glucose. * **RBCs (Option B):** This is a common point of confusion. **RBCs cannot use ketone bodies** because they lack mitochondria (ketolysis occurs in the mitochondrial matrix). However, in the context of this specific question, **Hepatocytes** is the most definitive answer regarding the specific absence of the enzyme Thiophorase. *Note: If both are options, Hepatocytes is the classical biochemical answer for "lack of enzyme."* * **Skeletal Muscles (Option C):** Extrahepatic tissues like skeletal and cardiac muscles are the primary consumers of ketone bodies during early starvation. **High-Yield Facts for NEET-PG:** 1. **Rate-limiting enzyme of Ketogenesis:** HMG-CoA Synthase (Mitochondrial). 2. **Organelle:** Ketogenesis and Ketolysis both occur in the **Mitochondria**. 3. **Ketone bodies:** Acetoacetate, 3-hydroxybutyrate, and Acetone (a non-metabolizable waste product). 4. **Key Deficiency:** Liver lacks **Thiophorase**, preventing a futile cycle.

Q: In the well-fed state, what inhibits the activity of Carnitine Palmitoyl Transferase-1 located in the outer mitochondrial membrane?

Malonyl-CoA. **Explanation:** The correct answer is **Malonyl-CoA**. This is a classic example of metabolic regulation designed to prevent a "futile cycle" (simultaneous synthesis and breakdown of fatty acids). **1. Why Malonyl-CoA is correct:** In the **well-fed state**, insulin levels are high, leading to increased fatty acid synthesis in the cytosol. The first committed step of lipogenesis is the conversion of Acetyl-CoA to Malonyl-CoA by the enzyme *Acetyl-CoA Carboxylase (ACC)*. **Malonyl-CoA** acts as a potent allosteric inhibitor of **Carnitine Palmitoyl Transferase-1 (CPT-1)**. By inhibiting CPT-1, Malonyl-CoA prevents the transport of long-chain fatty acids into the mitochondria for β-oxidation. This ensures that while the body is actively synthesizing fat, it is not simultaneously burning it. **2. Why other options are incorrect:** * **Glucose:** While high glucose levels trigger the insulin release that leads to Malonyl-CoA production, glucose itself does not directly bind to or inhibit CPT-1. * **Acetyl-CoA:** This is a precursor for both the TCA cycle and lipogenesis. While it is used to form Malonyl-CoA, it does not directly inhibit CPT-1. * **Pyruvate:** Pyruvate is the end-product of glycolysis. It enters the mitochondria to be converted into Acetyl-CoA but has no direct regulatory effect on the carnitine shuttle. **High-Yield Clinical Pearls for NEET-PG:** * **CPT-1 Location:** It is located on the **outer** mitochondrial membrane, whereas CPT-2 is on the inner membrane. * **Rate-Limiting Step:** CPT-1 is the rate-limiting step for **β-oxidation** of fatty acids. * **Deficiency:** CPT-1 deficiency typically presents as non-ketotic hypoglycemia and hepatomegaly, often triggered by fasting. * **Key Concept:** Insulin → Stimulates ACC → ↑ Malonyl-CoA → Inhibits CPT-1 → ↓ Fatty acid oxidation.

Q: Which of the following is an activator of LCAT?

Apolipoprotein AI. **Explanation:** **Lecithin-Cholesterol Acyltransferase (LCAT)** is a plasma enzyme synthesized by the liver that plays a pivotal role in **Reverse Cholesterol Transport (RCT)**. It catalyzes the transfer of a fatty acid from the second position of phosphatidylcholine (lecithin) to the free cholesterol present on the surface of High-Density Lipoprotein (HDL) particles. * **Why Option B is Correct:** **Apolipoprotein AI (Apo A-I)** is the major structural protein of HDL. It acts as a specific cofactor and **obligatory activator** of LCAT. By activating LCAT, Apo A-I facilitates the conversion of free cholesterol into hydrophobic cholesterol esters, which then move into the core of the HDL particle, transforming nascent discoid HDL into mature spherical HDL. **Analysis of Incorrect Options:** * **Apolipoprotein E:** Primarily serves as a ligand for the LDL receptor and the LRP (LDL Receptor-Related Protein), mediating the hepatic uptake of chylomicron remnants and IDL. * **Apolipoprotein B48:** Unique to chylomicrons; it is essential for the assembly and secretion of chylomicrons from the intestinal mucosa. * **Apolipoprotein B100:** Found in VLDL, IDL, and LDL; it acts as the primary ligand for the LDL receptor. **High-Yield Clinical Pearls for NEET-PG:** * **LCAT Deficiency:** Leads to **Fish-eye disease** (partial deficiency) or **Classical LCAT deficiency**, characterized by corneal opacities, hemolytic anemia, and renal failure. * **ACAT vs. LCAT:** While LCAT works in the *plasma* (extracellular), **ACAT** (Acyl-CoA:cholesterol acyltransferase) works *intracellularly* to store cholesterol. * **Reverse Cholesterol Transport:** This process is why HDL is termed "Good Cholesterol," as it clears excess cholesterol from peripheral tissues to the liver.

Question 1

Hypertriglyceridemia is not a feature of which of the following conditions?

Accepted Answer

Alcoholism

Answer

Obesity

Answer

Diabetes mellitus

Answer

Pregnancy

Question 2

Which food item contains the maximum cholesterol content?

Accepted Answer

Egg

Answer

Coconut Oil

Answer

Hydrogenated Fats

Answer

Ghee

Question 3

Which one of the following is of highest predictive value in the morbidity of coronary heart disease?

Accepted Answer

Apolipoprotein B

Answer

Lipoprotein A

Answer

Apolipoprotein A

Answer

Low density lipoprotein

Question 4

All of the following statements about fatty acid synthesis are true, except:

Accepted Answer

Palmitoleic acid is the end product

Answer

Occurs in cytosol

Answer

Citrate shuttle is required

Answer

Acetyl CoA is the immediate substrate

Question 5

Malonyl coenzyme A decarboxylase has an activity of how many enzymes?

Accepted Answer

2

Answer

1

Answer

3

Answer

4

Question 6

Bile acids are derived from what substance?

Accepted Answer

Cholesterol

Answer

Fatty acids

Answer

Bilirubin

Answer

Proteins

Question 7

What is the principal precursor of cholesterol?

Accepted Answer

Acetate

Answer

Citrate

Answer

Glycerol

Answer

Lanosterol

Question 8

Which of the following uses ketone bodies, except?

Accepted Answer

Hepatocytes

Answer

Brain

Answer

RBCs

Answer

Skeletal muscles

Question 9

In the well-fed state, what inhibits the activity of Carnitine Palmitoyl Transferase-1 located in the outer mitochondrial membrane?

Accepted Answer

Malonyl-CoA

Answer

Glucose

Answer

Acetyl-CoA

Answer

Pyruvate

Question 10

Which of the following is an activator of LCAT?

Accepted Answer

Apolipoprotein AI

Answer

Apolipoprotein E

Answer

Apolipoprotein B48

Answer

Apolipoprotein B100

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?